Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 3/20 | 0.33 |
| ▸ | CA5A | P35218 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10935171 | 0.83 | — | — | |
| SCHEMBL1789133 | 0.79 | — | — | |
| SCHEMBL6424273 | 0.77 | ACHE (0.42) | ACHECA12CA1CA2CA4 | |
| SCHEMBL23671129 | 0.72 | — | — | |
| SCHEMBL8340924 | 0.72 | ACHE (0.44) | ACHE | |
| SCHEMBL19348595 | 0.72 | ACHE (0.39) | ACHE | |
| SCHEMBL777833 | 0.72 | ACHE (0.59) | ACHE | |
| SCHEMBL6423255 | 0.72 | ACHE (0.39) | ACHESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL16450268 | 0.72 | — | — | |
| SCHEMBL19348615 | 0.72 | ACHE (0.39) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183355-B2 | Method for the synthesis of oligonucleotide derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-05-22 | — | — | US | disclosed |
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2011-10-06 | — | — | US | disclosed |
| US-7951926-B2 | Method for the synthesis of oligonucleotide derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-05-31 | — | — | US | disclosed |
| US-20090142849-A1 | Stable Oxygen Isotope Labeling of Pre-existing Phosphoryl Groups on Phosphomolecules for Modification-Specific Mass Spectrometry | UNIVERSITY OF CONNECTICUT (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090124571-A1 | METHOD FOR THE SYNTHESIS OF OLIGONUCLEOTIDE DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-05-14 | — | — | US | disclosed |
| EP-2021351-A2 | METHOD FOR THE SYNTHESIS OF TRIAZOLE-CONTAINING OLIGONUCLEOTIDE DERIVATIVES | Centre National de la Recherche Scientifique (FR) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007125429-A2 | METHOD FOR THE SYNTHESIS OF TRIAZOLE- CONTAINING OLIGONUCLEOTIDE DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124571-A1 | METHOD FOR THE SYNTHESIS OF OLIGONUCLEOTIDE DERIVATIVES | MSN, RNGTT, DCLRE1B | ACHE 4098/4885CA12 4381/4885CA1 4769/4885 |
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | MSN, RNGTT, DCLRE1B | ACHE 4098/4885CA12 4381/4885CA1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.